We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    YH003005
Previous Study | Return to List | Next Study

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05176509
Recruitment Status : Recruiting
First Posted : January 4, 2022
Last Update Posted : April 7, 2022
Sponsor:
Information provided by (Responsible Party):
Eucure (Beijing) Biopharma Co., Ltd

Brief Summary:
A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: YH003 Drug: YH001 Drug: Pembrolizumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors
Actual Study Start Date : April 5, 2022
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention/treatment Drug: YH003
YH003 will be administered intravenously over 60 minutes every 21-day cycle.

Drug: YH001
YH001 will be administered intravenously over 60 minutes every 21-day cycle.

Drug: Pembrolizumab
Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.




Primary Outcome Measures :
  1. Adverse events (AEs) [ Time Frame: up to 1 year after the last dosing ]
    The safety will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0

  2. Maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) [ Time Frame: up to 1 year after the last dosing ]
    The MTD and/or RP2D will be determined based on the data of safety and tolerability



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Subjects must have the ability to understand and willingness to sign a written informed consent document.
  • 2. Subjects must have histologically advanced or cytologically confirmed solid tumor.
  • 3. Subjects have progressed on after treatment with at least one standard therapy, or intolerant of the standard therapy, or no standard therapy accessible to the patients due to any reason
  • 4. Subject must have at least 1 unidimensional measurable disease by RECIST 1.1(Eisenhauer et al., 2009).
  • 5. Subjects must be age 18 years or older.
  • 6. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • 7. Life expectancy ≥3 months based on investigator's judgement.
  • 8. Subjects must meet the following laboratory values at the screening
  • 9. Women of reproductive potential must have negative serum beta human chorionic gonadotropin (β -HCG) pregnancy test within 7 days of the first dose of study drugs.
  • 10. Women of reproductive potential who are sexually active with a non-sterilized male must consistently use highly effective contraception/birth control between signing of the informed consent and 120 days after the last administration of the study drugs.

Exclusion Criteria:

  • 1. Subjects have another active invasive malignancy within 5 years
  • 2. Subjects must not have received any anticancer therapy or another investigational agent within the longer of 4 weeks or 5 half-lives before the first dose of the study treatment
  • 3. Subjects with a history of ≥ Grade 3 immune-related adverse events resulted from previous immunotherapy.
  • 4. History of clinically significant sensitivity or allergy to monoclonal antibodies and their excipients or known allergies to antibodies produced from Chinese hamster ovary cells, which in the opinion of the Investigator suggests an increased potential for an adverse hypersensitivity to YH003, YH001 or Pembrolizumab.
  • 5. Primary central nervous system (CNS) malignancies or symptomatic CNS metastases.
  • 6. History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis, or history of interstitial lung disease.
  • 7. Subjects must not have a known or suspected history of an autoimmune disorder
  • 8. Clinically uncontrolled intercurrent illness, including active coagulopathy, uncontrolled diabetes, psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies.
  • 9. Has an active infection requiring systemic therapy.
  • 10. Severe cardiovascular disease including symptomatic congestive heart failure (New York Heart Association class III or IV), unstable angina, uncontrolled hypertension, active coagulopathy, uncontrolled diabetes (blood glucose > 250 mg/dl), uncontrolled peritoneal effusion, cardiac arrhythmia, a history of myocardial infarction within 6 months or a history of arterial thromboembolic event and pulmonary embolism within 3 months of the first dose of investigational agent.
  • 11. QTcF> 480 ms at baseline; no concomitant medications that would prolong the QT interval; no family history of long QT syndrome.
  • 12. Subjects must not have active infection of human immunodeficiency virus (HIV), hepatitis B, hepatitis C or Covid-19.
  • 13. Subjects must not have a history of primary immunodeficiency.
  • 14. Subjects from endemic area will be specifically screened for tuberculosis. Subjects with active tuberculosis are excluded. Subjects who have received BCG vaccination may have a false positive PPD test. These subjects are eligible if they have a negative Interferon Gamma Release Assay (IGRA).
  • 15. Subjects must not receive concurrent or prior use of an immunosuppressive agent within 4 weeks of the first dose
  • 16. Major surgery within 4 weeks prior to study entry and Minor surgery within 2 weeks prior to the first dose.
  • 17. Subjects must not have received any vaccine within 28 days before the first dose, and subjects, if enrolled, should not receive live vaccines during the study or for 180 days after the last dose.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05176509


Locations
Layout table for location information
Australia, New South Wales
Blacktown Cancer and Haematology Centre, Clinical Trials, Block C, Level 3, 18 Blacktown Road Recruiting
Blacktown, New South Wales, Australia, 2148
Contact: Amanda Bryant    2867 05069    Amanda.Bryant1@Health.nsw.gov.au   
"Oncology Clinical Trial Unit St George Private Hospital 1 South Street" Recruiting
Kogarah, New South Wales, Australia, 2217
Contact: Tracy Liaw    2 8594 5785    LiawT@ramsayhealth.com.au   
Australia, Victoria
55 Commercial Rd, Level 2 WBRC Recruiting
Melbourne, Victoria, Australia
Contact: Nikki Cross    390763534    N.Cross@alfred.org.au   
Level 3, Suite 7, North Building, Frankston Private, 5 Susono Way, Frankston Recruiting
Prahran, Victoria, Australia
Contact: Albert Goikhman    3 9113 1307    ag@paso.com.au   
Sponsors and Collaborators
Eucure (Beijing) Biopharma Co., Ltd
Layout table for additonal information
Responsible Party: Eucure (Beijing) Biopharma Co., Ltd
ClinicalTrials.gov Identifier: NCT05176509    
Other Study ID Numbers: YH003005
First Posted: January 4, 2022    Key Record Dates
Last Update Posted: April 7, 2022
Last Verified: December 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents